Amendments to the Specification:

Please replace the paragraph beginning at page 10, line 3 of the specification with the following:

The minimum treatment dose of the GnRH ~~agonists~~ antagonists Cetrorelix, ANTRARELIX®, Antide, and Ramorelix for the intravenous administration form in the above-cited list corresponds to the dosage which is known for other indications at the proper approval board or described in the Deutsche Pharmazeutische Stoffliste or in the literature and is administered, for example, for Antide: Fattinger et al., 1996, Am. J. Physiol. 271 (Endocrinol. Metab. 34) E775-E787. The same is true for the GnRH antagonists as described in US patent 5,480,969, UK patent GB 2 246782 B, and US patent 5,198,533.